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Abstract
Objectives The aim of this study is to provide relevant and
accurate information on prevalence and treatment patterns
of anaemia in Belgian cancer patients.
Methods The Anaemia Day 2008 survey was a single visit,
multi-centre, non-interventional study in adult cancer patients
under systemic therapy (chemotherapy, hormonal, immuno-
logical and/or targeted therapy) and/or radiotherapy. Efforts
were made to enrol the maximum number of patients seen in
each centre that day. Patients signed an informed consent and
relevant data were collected from their files, i.e. disease and
disease stage, cancer therapy and anti-anaemic treatment,
including transfusions and the use of erythropoietin stimulat-
ing agents (ESA). A blood count of each included patient was
performed. Haemoglobin (Hb) values (grams per decilitre)
were classified into four categories to assess the severity of
anaemia, as defined byWHO: no anaemia: Hb≥12 g/dL; mild
10≤Hb≤11.9 g/dL; moderate 8≤Hb≤9.9 g/dL; severe Hb<
8 g/dL. Univariate and multivariate analyses were carried out
with anaemia as the dependent variable.
Results A total of 1,403 eligible patients aged 63±13 years
(mean age±SD)were enrolled in 106 oncology or haematology
centres. The mean Hb level (±SD) was 11.6 g/dL (±1.8 g/dL)
and the prevalence of anaemia (Hb<12 g/dL) was 55.7% (95%
CI, 53.1–58.3%), respectively, 35.9% mild, 17.8% moderate
and 2.1% severe anaemia. Anaemia was more frequent in
females than in males, and in patients with haematological
malignancies (73.4%) than in those with solid tumours (51.4%;
p<0.001). Anaemia prevalence was higher in hospitalised
patients (75.5%) compared to those seen in one-day-clinic
(54.3%) or in consultation (33.9%; p<0.001), and in patients
treated with chemotherapy (61.3%) compared to those
receiving radiotherapy (34.4%) or hormonal therapy
(19.5%; p<0.001). There was a clear correlation between
severity of anaemia and WHO performance status (p<
0.001). Among anaemic patients, 53.1% received no
treatment (mean Hb 10.8±0.9 g/dL). Among the anaemic
patients who received therapy for their anaemia (mean Hb
9.7±1.1 g/dL), the most frequent treatments were RBC
transfusions (42%), ESA (34.6%), transfusions+ESA
(12%), ESA+iron (7.9%) and iron alone (3.5%). Compar-
ison to the ECAS survey shows that there has been no
major change in attitude towards anaemia management in
the last decade.
Conclusion This survey shows that cancer-related anaemia
is still frequently observed in cancer patients. Even if in our
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study ESA were used more frequently than about 10 years
ago, still a large amount of anaemic patients who could be
treated for anaemia according to EORTC guidelines, were
not.
Keywords Anaemia . Survey . Erythropoietin stimulating
agents (ESA)
Introduction
Anaemia is common in patients with malignancy, particu-
larly if under chemotherapy [1]. The impact of anaemia on
the physical and psychological health status of cancer
patients is well known [1, 2]. Therefore, optimal manage-
ment of anaemia appears to be an important component of
cancer treatment. Particularly important may be the effect
of mild-to-moderate anaemia on patients who might not be
treated according to the European Organisation for Re-
search and Treatment of Cancer (EORTC) guidelines [3],
patients with haemoglobin between 10.0 and 11.9 g/dL.
Recent data on prevalence and incidence of anaemia in
cancer patients, particularly within the routine practice of
individual countries, are almost non-existing. This study
describes the methodology of the Anaemia Day and
provides patient data that focus on the prevalence of
anaemia, the effect of mild, moderate and severe anaemia
on performance status, and anaemia treatment patterns.
Material and methods
Study design The “Anaemia Day 2008” survey is a one
visit only, multi-centre and non-interventional study in
cancer patients presenting at Belgian oncology and haema-
tology centres. Inclusion criteria were: age 18 years or
older, bearing a solid tumour or a haematological malig-
nancy, being under systemic therapy and/or radiotherapy,
having a blood count foreseen the day of the scheduled visit
and having given a written informed consent.
Data collection The following data were collected: date of
the visit, age, geographical region, gender, WHO perfor-
mance status, site of visit (hospitalisation, one-day hospital
unit, consultation), reason of visit (follow-up, active
treatment, supportive care, other), date of the initial
diagnosis of cancer, age of the patient at diagnosis. The
tumour was classified as solid or haematological and the
current tumour extension was reported as primary, locally
advanced or metastatic. Recent therapy (last 4 weeks before
the recorded visit) was reported as chemotherapy, radio-
therapy, hormonal therapy, or other (immunological thera-
py, targeted therapy, other). For chemotherapy, the intention
of treatment (adjuvant, neoadjuvant, advanced stage), the
actual number of cycles and the schedule (containing
platinum, anthracyclines, taxanes or others) were also
recorded.
Blood haemoglobin (Hb) levels (grams per decilitre) were
measured on the day of visit and classified into four
categories in order to assess the severity of anaemia: none,
Hb≥12 g/dL; mild, 10≤Hb≤11.9 g/dL; moderate, 8≤Hb≤
9.9 g/dL; severe, Hb<8 g/dL. Anaemia-related symptoms
occurring during the 4 weeks preceding the day of the survey
were also recorded. The following information about anti-
anaemic treatment was collected: time when treatment was
started (during past 4 weeks or on day of survey), type of
treatment (none, RBC transfusion, erythropoiesis-stimulating
agents (ESA), iron supplementation), the Hb level at
initiation of treatment and the targeted Hb level.
Statistical analyses The primary endpoint of the study was
prevalence and severity of anaemia (mild, moderate,
severe) in Belgian cancer patients treated with systemic
therapy and/or radiotherapy in oncology/haematology
centres. Secondary endpoints included the description of
the characteristics of cancer patients as well as their current
management of anaemia.
Results were expressed as mean±standard deviation
(SD), median and range for quantitative variables. The
relationship between two variables was assessed by the
correlation coefficient or by the chi-square test in case of
two categorical variables. Mean values from two groups
were compared by the Student t test (corrected for unequal
variances if necessary) or by a non-parametric test (e.g.
Wilcoxon test) when the variable was not normally
distributed. Analyses of variance or the non-parametric
Kruskal–Wallis test were applied for the comparison of
several groups. The classical chi-square test for contingency
tables was used for comparing proportions.
Logistic regression analysis was used to measure the
association between anaemia and a set of covariates. The
odds ratio (OR) was computed with its 95% confidence
interval (CI) to measure the association between the risk of
anaemia and the covariates. Ordinal logistic regression
analysis was also used to relate the severity of anaemia with
the same set of covariates.
Results were considered to be significant at the 5%
significant level (p<0.05).
Results
A total of 1,403 eligible patients aged 63.1±13.0 years
were enrolled in 106 oncology or haematology centres. The
mean time (±SD) since first diagnosis of cancer was 2.1±
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3.2 years (range, 0–24 years). Table 1 summarises the
demographics and patient characteristics.
For the 1,403 included patients, the prevalence of
anaemia was 55.7% with a mean Hb level (±SD) of 11.6
±1.8 g/dL. The classification of the cancer patients
according to their haemoglobin levels revealed that 44.3%
were not anaemic, 35.9% presented a mild anaemia, 17.8%
a moderate anaemia and 2.1% a severe anaemia.
Table 2 displays anaemia prevalence by tumour type and
extent of cancer. Only 13.8% of patients with solid tumours
had moderate or severe anaemia, while the proportion was
44.2% in those with haematological malignancies (p<
0.001). In solid tumour patients, the level of anaemia
differed significantly according to the location of the
primary tumour, with more moderate and severe anaemia
in patients with gynaecological and head-and-neck tumours
(p<0.0001). For haematological malignancies, more mod-
erate and severe anaemia were reported in patients with
myelodysplastic syndromes (p<0.0001). Anaemia was
significantly associated with the extent of cancer. Patients
with metastasis or locally advanced cancer had significantly
more often moderate to severe anaemia than patients with
only a localised solid tumour.
There was a trend for higher incidence of anaemia in
female. From a multivariate standpoint, female were 1.8
times more at risk of anaemia than men.
Table 3 shows the prevalence of anaemia according to
the treatment received. When analysed by type of treatment
at enrolment, 61.3% of patients receiving chemotherapy,
34.4% of those receiving radiotherapy and 19.5% of those
receiving hormonal therapy were anaemic.
There was a clear correlation between the severity of
anaemia and WHO performance status (p<0.0001). There
were more patients at enrolment with poor-performance
status at lower Hb levels than at higher Hb levels. WHO
scores of 2–4 were recorded for 65% of patients with Hb<
8.0 g/dL, 48% of those with Hb between 8.0 and 9.9 g/dL,
22% of those with Hb between 10.0 and 11.9 g/dL and 1%
of those with Hb>12 g/dL (Table 4).
Of patients who were ever anaemic (the day of survey or
past 4 weeks preceding the visit; n=782), 53.1% received
no treatment. The majority (83%) of untreated anaemic
patients had Hb levels between 10.0 and 11.9 g/dL; 17%
had Hb levels between 8.0 and 9.9 g/dL, and 0.1% had Hb
levels <8 g/dL.
Table 5 shows the percentage of patients who received
treatment for their anaemia. For the 46.9% of patients who
received treatment, the most frequent therapy was transfu-
sion, either alone (42%) or in combination with ESA (12%).
The frequencies of ESA treatment alone or with iron were
35% and 8%, respectively, and that of iron alone was 3.5%.
The mean Hb level for initiating treatment was 9.7 g/dL in
our study, with the level for transfusion being 9.2 g/dL and
the level for ESA being 10.2 g/dL.
Discussion
This survey shows that anaemia is still frequently observed
in Belgian cancer patients under treatment, with a general
prevalence of 55.7%, including 20% with moderate to
severe anaemia. Anaemia was more frequent in patients
with haematological tumours (73.4%) than in patients with
solid tumours (51.4%). Among solid tumour patients,
Table 1 Clinical characteristics of the 1,403 patients enrolled in the
study
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anaemia was more severe in patients with gynaecological
and head-and-neck tumours. Among patients with haema-
tological malignancies, anaemia was more prominent in
those with myelodysplastic syndromes.
The prevalence of anaemia found in our survey is higher
than in previous reports. In Japanese and Turkish studies,
44% of the patients were anaemic at the start of their
chemotherapy [4, 5]. The prevalence of anaemia at enrol-
ment in the European and Australian Cancer Anaemia
surveys (ECAS, ACAS) was 39% and 35%, respectively,
with 10% and 8% having moderate to severe anaemia [1,
6]. This difference could be explained by the exclusion of
untreated patients in the ECAS and ACAS studies. In the
ECAS study, the prevalence of anaemia among patients
receiving chemotherapy was 62.7%, a figure comparable to
ours.
We observed a clear correlation between anaemia and
low-performance status. More than half of the patients with
severe anaemia had a WHO score of 2–4, but performance
scores of 2–4 were also noted for 22% of patients with
No anaemia Mild anaemia Moderate anaemia Severe anaemia
Primary tumour
Solid tumour 547 (48.6) 423 (37.6) 143 (12.7) 12 (1.1)
Breast 159 (55.8) 92 (32.3) 32 (11.2) 2 (0.7)
Colorectal 212 (52.7) 153 (38.1) 35 (8.7) 2 (0.5)
Urogenital 44 (61.1) 19 (26.4) 8 (11.1) 1 (1.4)
Lung 82 (36.4) 101 (44.7) 38 (16.8) 5 (2.2)
Gynaecologic 16 (28.1) 28 (47.5) 13 (22.0) 2 (3.4)
ORL 17 (38.6) 17 (38.6) 10 (22.7) 0 (0.0)
Other 17 (46.0) 13 (35.1) 7 (18.9) 1 (1.4)
Haematological tumour 74 (26.6) 81 (29.1) 106 (38.1) 17 (6.1)
Lymphoma/myeloma 42 (27.1) 57 (36.8) 52 (33.6) 4 (2.6)
Leukaemia 20 (22.7) 21 (23.9) 41 (46.6) 6 (6.8)
Myelodysplasia 1 (5.3) 3 (15.8) 10 (52.6) 5 (26.3)
Other 11 (68.8) 0 (0.0) 3 (18.8) 2 (12.5)
Tumour extent(solid tumours)
Primary 176 (65.4) 84 (31.2) 9 (3.4) 0 (0.0)
Locally advanced 86 (45.5) 71 (37.6) 29 (15.3) 3 (1.6)
Metastatic 285 (42.7) 268 (40.2) 105 (15.7) 9 (1.4)
Table 2 Distribution of the
grade of anaemia according to
the type of primary tumour and
tumour extension
Treatment No anaemia Mild anaemia Moderate anaemia Severe anaemia
Chemotherapy 435 (38.7) 455 (40.5) 208 (18.5) 26 (2.3)
Type of chemotherapy
Neoadjuvant 97 (44.1) 91 (41.4) 28 (12.7) 4 (1.8)
Adjuvant 38 (45.8) 29 (34.9) 16 (19.3) 0 (0.0)
Advanced stage 278 (37.6) 306 (41.4) 138 (18.7) 18 (2.4)
Components
Platinum-based 162 (39.4) 178 (43.3) 64 (15.6) 7 (1.7)
Taxane-based 35 (31.3) 55 (49.1) 21 (18.8) 1 (0.9)
Anthracyclines-based 47 (31.8) 65 (43.9) 29 (19.6) 7 (4.7)
Other 226 (40.4) 209 (37.4) 111 (19.9) 13 (2.3)
Radiotherapy 103 (65.5) 35 (22.3) 19 (12.1) 0 (0.0)
Hormonotherapy 66 (80.5) 10 (12.2) 6 (7.3) 0 (0.0)
Immunological therapy 36 (50.0) 17 (23.6) 17 (23.6) 2 (2.8)
Targeted therapy 57 (48.3) 35 (29.7) 22 (18.6) 4 (3.4)
Other 23 (34.3) 18 (26.9) 24 (35.8) 2 (3.0)
Table 3 Distribution of the
grade of anaemia according to
the type of treatment
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haemoglobin levels between 10.0 and 11.9 g/dL. This
relationship between anaemia and low-performance status
was already demonstrated in the ECAS study and is
consistent with the correlation reported between the
increase in haemoglobin levels with ESA and the improve-
ment of quality of life [7–9]. In the large trial of Demetri et
al., patients who achieved an increase in haemoglobin level
of 2 g/dL or greater had the largest increase in quality of
life, even in the case of progressive disease [7].
Despite evidence that even mild anaemia can adversely
affect quality of life, many clinicians still don't treat
anaemic patients. In our survey, 53.1% of the anaemic
patients received no treatment for their anaemia. Most of
them (35.4%) had haemoglobin levels between 10.0 and
11.9 g/dL, but another 15% of the untreated patients had a
haemoglobin level<10 g/dL. In the ECAS study, anaemia
treatment was initiated in approximately 40% of anaemic
patients [1].
In our survey, the most frequently used treatments were
RBC transfusions (42%), ESA (34.6%), transfusions+ESA
(12%), ESA+iron (7.9%) or iron alone (3.5%). In compar-
ison, in the ECAS and ACAS studies, transfusions were
given to 17% and 36% and ESA to 15% and 2% of the
patients, respectively. The mean haemoglobin level for
initiating treatment was 9.7 g/dL in our study, with the level
for transfusion being 9.2 g/dL and that for ESA 10.2 g/dL.
The trigger for initiating transfusions was 9.7 g/dL both in
the ECAS and ACAS studies [1, 6].
Several studies with ESA have raised a number of safety
issues, including an increased risk of thromboembolic
events and a negative impact on survival [10–12]. In a
recent meta-analysis based on individual patient data from
randomised trials, the HR for overall mortality was 1.06
(95% CI, 1.00–1.12) [13]. This meta-analysis also included
patients not receiving treatment for their cancer or receiving
treatments other than chemotherapy The HR of death was
1.10 (95% CI, 0.98–1.24) in patients treated with chemo-
therapy and few of the included trials were restricted to the
approved indications of ESA, making it difficult to
generalise these results.
The EORTC guidelines recommend that ESAs should be
initiated at an Hb level of 9–11 g/dL in cancer patients
receiving chemotherapy or radiochemotherapy, based on
anaemia-related symptoms [3]. And ESA therapy may be
considered in selected asymptomatic patients receiving
chemotherapy with a Hb level of 11–11.9 g/dL if this
would prevent a further decline in Hb. Such a decision
should take into account an individual's Hb level and the
type, intensity, and duration of chemotherapy. The aim of
treatment with ESA is to achieve an Hb concentration of
about 12 g/dL, without exceeding this target. For that
reason, the new label for ESA suggests to initiate treatment
to patients with syptomatic anaemia in order to increase
haemoglobin, without exceeding the target of 12 g/dL.
This study indicates that Belgian physicians respect these
recommendations: the Hb trigger to start ESA treatment was
10.2 g/dL and the target was 11.6 g/dL. Our Belgian treatment
patterns are congruent with the findings from the Anaemia
Cancer Treatment Study (ACT), where most patients were
treated per guidelines [14]. In the ACT study, after treatment
with ESA, the Hb increased by 1.34 g/dl, without concom-
itant rise in WHO score. We were not able to analyse the
correlation between use of ESA and anaemia-related symp-
toms because of the design of the study that was a one-day
snapshot of a large population of cancer patients. In this
survey, only patients under systemic therapy or radiotherapy
were included. For this reason, it is impossible to assess
potential off-label uses, but as in Belgium reimbursement of
ESA is restricted to patients under chemotherapy, such off-
label use would be expected to be very low.
In conclusion, this survey shows that cancer-related
anaemia is still frequently observed in patients in Belgium
and that it correlates significantly with poor performance
status. Even if in our survey ESA were used more
frequently than 10 years ago, a significant proportion of
patients with moderate and probably symptomatic anaemia
who could be treated for anaemia according to the EORTC
guidelines did not.













0 286 (63.0) 146 (32.2) 20 (4.4) 2 (0.4)
1 274 (43.1) 245 (38.5) 109 (17.1) 8 (1.3)
2 50 (21.2) 89 (37.7) 82 (34.8) 15 (6.4)
3 8 (13.3) 20 (33.3) 28 (46.7) 4 (6.7)
4 3 (18.8) 4 (25.0) 9 (56.3) 0 (0)
Table 5 Number of anaemic patients who received treatment
n Hb level (g/dL)
Never treated anaemic patients 415 10.8±0.9







Treatment could be given on the day of the visit or in the past 4 weeks
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